Dacarbazine

Thermosome's lead compound THE001, a thermosensitive liposomal formulation of doxorubicin, has received U.S. FDA Orphan Drug Designation for soft tissue sarcoma treatment, complementing its existing European designation.

• Foresight Diagnostics and University of Washington have launched the PRECISE-HL trial using ctDNA-based minimal residual disease testing to personalize treatment for advanced classical Hodgkin lymphoma patients. • The trial aims to reduce chemotherapy exposure for early responders by transitioning them to nivolumab monotherapy after only four cycles of combination therapy, potentially minimizing long-term side effects. • Over 70% of patients in previous research achieved undetectable MRD by the end of cycle two with PD-1 inhibitor plus chemotherapy, suggesting many patients may benefit from reduced treatment intensity.

Sun Pharmaceutical Industries and Philogen have successfully completed patient enrollment in the Phase III FIBROSARC trial for Soft Tissue Sarcoma, with key readouts expected between March and June 2025.

• A phase 1/2 study demonstrates that Opdivo combined with AVD chemotherapy achieves 79% progression-free survival and 97% overall survival at three years in older cHL patients. • The treatment regimen proves effective across various geriatric conditions, with half of the patients experiencing grade 3-4 side effects, though only 10% discontinued treatment. • The combination therapy could establish a new standard of care for elderly Hodgkin lymphoma patients, according to Journal of Clinical Oncology editor-in-chief Dr. Jonathan W. Friedberg.

Talphera has reached an agreement with the FDA for a Prior Approval Supplement (PAS) review to reduce the number of patients in the NEPHRO CRRT study.